BioNexus Gene Lab (BGLC) Earnings Analysis

BioNexus Gene Lab (BGLC) has no confirmed upcoming earnings date. Trailing P/E -1.04.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BGLC next report earnings?

No confirmed upcoming earnings date is currently scheduled for BGLC. This page updates as the calendar is published.

BGLC earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.23 USDn/an/an/a
2026-04-14-0.53 USDn/an/an/a
2025-11-14-0.39 USDn/an/an/a
2025-08-18-0.34 USDn/an/an/a
2025-05-15-0.03 USDn/an/an/a
2025-04-15-0.19386 USDn/an/an/a
2024-11-15-0.2 USDn/an/an/a
2024-08-140.1 USDn/an/an/a

BGLC valuation and analyst view

Trailing P/E-1.04
Trailing EPS-1.20169 USD
Price / book0.46
Dividend yield0.00%
Market cap0.00B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is BioNexus Gene Lab (BGLC)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for BGLC. This page updates as the calendar is published.

Did BGLC beat earnings last quarter?

Consensus estimate data was not available for BGLC's 2026-05-15 report.

What is BGLC's current P/E ratio and EPS?

BGLC trades at a trailing P/E of -1.04 on trailing EPS of -1.2016870791299765 USD.

What do analysts rate BGLC?

BGLC has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.